HAS Healthcare Advanced Synthesis Achieves EcoVadis Gold Medal for the Fifth Consecutive Year
Biasca, Switzerland, September 2026
HAS Healthcare Advanced Synthesis (HAS) is proud to announce that it has once again been awarded the prestigious EcoVadis Gold Medal, marking the fifth consecutive year the company has received this important sustainability recognition.
In the 2026 assessment, HAS achieved an overall score of 87/100, placing the company in the 98th percentile among all companies evaluated by EcoVadis worldwide.
The new assessment represents a significant improvement compared to the previous year, with HAS increasing its overall score by 7 points and moving from the "Advanced" category to the "Exceptional" category within the EcoVadis rating framework. This achievement places the company in the 98th percentile and among the top 2% of organizations assessed worldwide.
The result reflects HAS's continued commitment to integrating sustainability principles across its business activities and value chain. The assessment highlighted strong performance in all evaluated areas, including:
- Environment: 91/100
- Labour & Human Rights: 86/100
- Ethics: 85/100
- Sustainable Procurement: 85/100
EcoVadis is one of the world's most trusted providers of business sustainability assessments, evaluating companies across environmental, social, ethical, and supply chain criteria. The recognition demonstrates HAS's dedication to responsible growth and continuous improvement while supporting customers in the development and manufacturing of complex pharmaceutical compounds.
"We are extremely proud to receive the EcoVadis Gold Medal for the fifth consecutive year. This achievement reflects the commitment of our entire organization to operating responsibly, reducing our environmental footprint, fostering an ethical and safe workplace, and promoting sustainable practices throughout our supply chain."
As a Swiss CDMO serving pharmaceutical and biotechnology companies worldwide, HAS views sustainability as a fundamental pillar of long-term value creation. The company will continue investing in initiatives that strengthen environmental performance, employee wellbeing, ethical governance, and responsible sourcing.
The company would like to thank all employees, customers, suppliers, and partners whose collaboration and dedication have contributed to this important milestone.
Sustainability remains a strategic priority for HAS Group, supporting responsible growth, operational excellence, and long-term value creation for customers, employees, shareholders, and society.
About HAS Healthcare Advanced Synthesis
HAS Healthcare Advanced Synthesis is part of the HAS Group, an integrated CDMO platform established in 2025 through the acquisition of Cerbios-Pharma SA. Rooted in decades of Swiss precision and built on more than forty years of combined experience, the HAS Group brings together advanced chemical and biological expertise within a single, fully integrated organization.
With a robust portfolio of established APIs and pharmaceutical products, the Group delivers innovative solutions across highly specialized technologies, including highly potent and complex small molecules, reduced folates, linker-payloads and Antibody-Drug Conjugates (ADCs).
We unite complementary capabilities in chemical and biological development, specializing in APIs, HPAPIs, anticancer compounds, linker-payloads, ADCs and reduced folates. Our end-to-end solutions guide projects from early-phase development through commercial supply, leveraging multiple GMP-certified sites across Switzerland.
Whether advancing early-stage research or scaling for global markets, HAS Group is your trusted partner to innovate, manufacture, and deliver.
For more information:
HAS Healthcare Advanced Synthesis SA
Biasca, Switzerland
Press Office:
Giacomo Braglia
Tel: +41 (0) 91 873 94 00